Clinical trials: Obesity and Metabolic Syndrome
Metabolic Syndrome, Diabetes
Evaluation of a Novel Self-Sampling Earwax Tool for Chronic Disease Biomarkers [TREARS STUDIES II]
Trears Biomarkers: A New Way to Manage Chronic Diseases Trears Biomarkers are changing how we care for chronic diseases by focusing on patients' needs.
- Conditions
- Metabolic Syndrome, Diabetes, Hypertension, Obesity and Obesity-related Medical Conditions
- Trial name
- Trears-II (NCT06932601)
- Volunteers
- 258 people
- Sponsor
- Trears
Weight Loss, Metabolic Syndrome
Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)
The use of continuous glucose monitoring (CGM) in earlier data has inspired behavioral changes leading to improved adherence to an exercise plan in individuals and eating habits in people with diabetes.
- Conditions
- Weight Loss, Metabolic Syndrome, Diabetes Mellitus, Type 2, Central Obesity
- Trial name
- NCT05874635
- Testing
- Continuous Glucose Monitor Device
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Signos Inc
Metabolic Syndrome
Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Male Volunteers
The purpose of this study is to investigate the safety and tolerability of MB12066 after multiple dose and to investigate the pharmacokinetic characteristics of MB12066 after multiple dose.
- Trial name
- NCT02338856
- Testing
- MB12066 200mg
- Where
- South Korea
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Yungjin Pharm. Co., Ltd.
Hyperphagia, Prader-Willi Syndrome
The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial
The goal of this clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS) when used in a long term setting. It will also teach us about the safety of ARD-101.
- Conditions
- Hyperphagia, Prader-Willi Syndrome, Hyperphagia in Prader-Willi Syndrome
- Trial name
- NCT07197034
- Testing
- ARD-101
- Where
- 30 sites in United States, Australia and 3 more
- Volunteers
- 19 people
- Sponsor
- Aardvark Therapeutics, Inc.
Overweight, Obesity
The Effect of the Treatment Program "Dr. Fedon Lindbergs Vektcoach" on Body Weight and Composition and Hormonal Profile
The background for the trial is a number of previous studies indicating that it is especially important to restrict the intake of carbohydrates when treating overweight and metabolic diseases in general.
- Conditions
- Overweight, Obesity, Metabolic Syndrome
- Trial name
- NCT01235208
- Testing
- The "Dr. Fedon Lindbergs Vektcoach" Treatment
- Where
- Norway
- Volunteers
- 44 people
- Sponsor
- Eurodiet Scandinavia AS
Prader-Willi Syndrome, Obesity
Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome
The purpose of this study is to evaluate efficacy and safety of ZGN-440 (beloranib) in obese adolescent and adult subjects with Prader-Willi Syndrome.
- Trial name
- bestPWS (NCT02179151)
- Testing
- ZGN-440 for Injectable Suspension
- Where
- 15 sites in United States
- Volunteers
- 108 people
- Sponsor
- Zafgen, Inc.
Psoriasis, Metabolic Syndrome
Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
This study was a randomized, open-label, parallel-group, active comparator controlled study with two treatment arms designed to answer the question whether the combination of Secukinumab with lifestyle intervention could…
- Trial name
- METABOLYX (NCT03440736)
- Testing
- Secukinumab, Life-style intervention
- Where
- 75 sites in Germany
- Volunteers
- 781 people
- Sponsor
- Novartis Pharmaceuticals
Metabolic Syndrome
VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt
Primary objective: To assess the effect of rimonabant on visceral fat area over a period of 12 months when prescribed with a mild hypocaloric diet in abdominally obese patients with metabolic syndrome Secondary objectives: To…
- Trial name
- VICTORIA (NCT00299325)
- Testing
- Rimonabant, Mild hypocaloric diet
- Where
- 9 sites in United States, Canada and 7 more
- Volunteers
- 254 people
- Sponsor
- Sanofi
Metabolic Syndrome, Obesity & Overweight
Evaluating the SWW Method Dietary Intervention for HbA1c and Weight Management as a Preventative Intervention in Women
This study evaluated the SWW Method®, a 12-week dietary and lifestyle intervention based on the carbohydrate-insulin model, in a healthy cohort of women aged 35-75.
- Conditions
- Metabolic Syndrome, Obesity & Overweight, Blood Glucose Monitoring, Type 2 Diabetes Prevention
- Trial name
- NCT07463417
- Testing
- SWW Method® Dietary and Lifestyle Intervention
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Sarah Wragge Wellness
Apnea, Sleep Disorders
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)
This study is being done to learn about the safety and effects of a study medicine called berobenatide (bear-oh-BEN-uh-tide). The study will see if berobenatide can help adults with breathing problems during sleep (obstructive…
- Conditions
- Apnea, Sleep Disorders, Overweight and/or Obesity
- Trial name
- NCT07823608
- Testing
- Berobenatide
- Where
- 8 sites in United States
- Volunteers
- 258 people
- Sponsor
- Pfizer
Acute Respiratory Failure, Coma
EASiVENT Study Comparing INTELLiVENT-ASV vs Non Automated Ventilation in Adult ICU Patients
The purpose of the study is to assess the safety and efficacy of INTELLiVENT-ASV (Adaptive Support Ventilation) in adult ICU patients comparing to non automated ventilation.
- Conditions
- Acute Respiratory Failure, Coma, Acute Respiratory Distress Syndrome (ARDS), Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT04400643
- Testing
- INTELLiVENT-ASV, Non-automated ventilation
- Where
- Portugal
- Volunteers
- 62 people
- Sponsor
- Hamilton Medical AG
Prader-Willi Syndrome
Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome
Prospective observational study developed to generate more evidence of the safety profile, clinical characteristics and outcomes of patients with PWS treated with VYKAT XR.
- Trial name
- NCT07450664
- Testing
- VYKAT XR
- Where
- 25 sites in United States
- Volunteers
- 200 people
- Sponsor
- Soleno Therapeutics, Inc.
COVID-19
Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection
A prospective, longitudinal, observational cohort study looking at patients following COVID-19 disease using multi-parametric magnetic resonance imaging (MRI) to assess the degree and prevalence of organ injury.
- Trial name
- COVERSCAN (NCT04369807)
- Testing
- Outpatient MRI
- Where
- 2 sites in United Kingdom
- Volunteers
- 693 people
- Sponsor
- Perspectum
Obesity, Over-weight
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics for certain doses of beloranib in obese subjects with Prader-Willi Syndrome.
- Conditions
- Obesity, Over-weight, Prader-Willi Syndrome
- Trial name
- NCT01818921
- Testing
- ZGN-440 sterile diluent, 1.2 mg ZGN-440 for injectable suspension, 1.8 mg ZGN-440 for injectable suspension
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Zafgen, Inc.
Carotid Artery Plaque, Arteriosclerosis
Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant
Objectives: Primary: To evaluate the effect of rimonabant 20-mg once daily in comparison with placebo, on the quantitative progression of atherosclerosis as assessed by carotid artery intima-media thickness (CIMT) Secondary: To…
- Conditions
- Carotid Artery Plaque, Arteriosclerosis, Obesity, Metabolic Syndrome X
- Trial name
- AUDITOR (NCT00228176)
- Testing
- Rimonabant
- Where
- 6 sites in United States, Canada and 4 more
- Volunteers
- 661 people
- Sponsor
- Sanofi
Prader-Willi Syndrome
A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome
The objective of this study is to assess the long-term safety and tolerability of Cannabidiol Oral Solution (CBD) in participants with Prader-Willi Syndrome.
- Trial name
- NCT03458416
- Testing
- Cannabidiol Oral Solution
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Radius Pharmaceuticals, Inc.
Respiratory Failure, Neuromuscular Disease
Ventilator Monitoring in Early Exacerbation Detection
The aim of this study is to determine whether respiratory disease exacerbations (a sudden worsening of symptoms) can be predicted by variables that are monitored by non-invasive ventilators (small machines that assist breathing)…
- Conditions
- Respiratory Failure, Neuromuscular Disease, Chest Wall Disorder, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT01644162
- Testing
- iVAPS ventilation
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- ResMed
Obese, Sleep Apnea, Obstructive
Eval EarlySense Bet Lowenstein Sleeplab
The study objective is to collect heart rate, respiration rate and motion data of patients admitted to sleep lab and to determine the accuracy level of the EarlySense system vs.
- Conditions
- Obese, Sleep Apnea, Obstructive, Central Apnea, Sleep Disorders
- Trial name
- NCT01978340
- Where
- Israel
- Volunteers
- healthy volunteers welcome
- Sponsor
- EarlySense Ltd.
Overweight, Obesity
Evaluation of a New Orange-Based Beverage Enriched With Polyphenols in Adult Humans
The purpose of this study is to evaluate the effects of a new orange juice-based beverage enriched in fiber and selected phenolic compounds (mainly flavanones) on features of metabolic syndrome and cardiovascular disease risk…
- Trial name
- BIONAOS (NCT01290250)
- Testing
- Orange juice based beverage enriched in polyphenols
- Where
- Spain
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- The Coca-Cola Company
Prediabetes, Insulin Resistance
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity
This Phase 2a study evaluates whether 12 weeks of treatment with investigational MOTS-c improves insulin sensitivity compared with placebo in adults with prediabetes and overweight/obesity.
- Conditions
- Prediabetes, Insulin Resistance, Overweight/Obesity
- Trial name
- MOTS-MET (NCT07505745)
- Testing
- MOTS-c (MDP), Route Subcutaneous injection, Regimen
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Hudson Biotech